Gene profile and response to treatment

Annals of Oncology

Volumn 16, Issue SUPPL. 2, 2005, Pages

  Smeds, J ^a   Miller, L D ^b   Bjohle J ^a   Hall, P ^a   Klaar, S ^a   Liu, E T ^b   Pawitan, Y ^a   Ploner, A ^a   Bergh, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; MESSENGER RNA; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CORRELATION COEFFICIENT; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC RISK; GENETIC SELECTION; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 21344468652     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi737     Document Type: Article

References (58)

1. Schwartsmann G, Ratain MJ, Cragg GM et al. Anticancer drug discovery and development throughout the world. J Clin Oncol 2002; 20: 47S-59S.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
4. Eifel P, Axelson JA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancerNovember 1-3, 2000. J Natl Cancer Inst 2001; 93: 979-989.
5. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365.
6. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679.
7. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
8. Sjogren S, Inganas M, Lindgren A et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462-469.
9. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-1266.
10. Paik S, Bryant J, Park C et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-1370.
11. Smith I, Dowsett M, on behalf of the IMPACT, Royal Marsden Hospital, United Kingdom. In Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. In Lippman ME (ed.). 82. 26th Annual San Antonio Breast Cancer Symposium 2003; S6, (Abstr 1).
12. Borg A, Baldetorp B, Ferno M et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994; 81: 137-144.
13. Carlomagno C, Perrone F, Gallo C et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14: 2702-2708.
14. Houston SJ, Plunkett TA, Barnes DM et al. Overexpression of c-erbB2 is an independent market of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999; 79: 1220-1226.
15. Elledge RM, Green S, Ciocca D et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998; 4: 7-12.
16. Fossati R, Confalonieri C, Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16: 3439-3460.
17. A'Hern RP, Ebbs SR, Baum MB. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 1988; 57: 615-618.
18. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 1413-1424.
19. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
20. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
21. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
22. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
23. Ahr A, Karn T, Solbach C et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002; 359: 131-132.
24. Huang E, Cheng SH, Dressman H et al. Gene expression predictors of breast cancer outcomes. Lancet 2003; 361: 1590-1596.
25. Piccart MJ, Loi S, van't Veer L, et al. Multi-center external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: are the results still outperforming the clinical-pathological criteria? Breast Cancer Res Treat 2004; 88 (Suppl 1): (Abstr 38).
26. Pawitan Y, Bjohle J, Amler L et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy-derived and validated in two population based cohorts. Manuscript 2005.
27. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
28. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
29. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-10398.
30. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
31. Hedenfalk I, Duggan D, Chen Y et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344: 539-548.
32. Miller LD, Smeds J, George J et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects and patient survival. 2005; Manuscript.
33. Gruvberger S, Ringner M, Chen Y et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001; 61: 5979-5984.
34. West M, Blanchette C, Dressman H et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001; 98: 11462-11467.
35. Lin C-Y, Strom A, Kietz S et al. Microarray analysis reveals inhibitory mechanisms of estrogen receptor beta on tumor cell proliferation and identifies markers predictive of clinical outcome in primary breast cancer. 2005; Manuscript.
36. Chang JC, Wooten EC, Tsimelzon A et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369.
37. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
38. Ellis M, Davis N, Coop A et al. Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res 2002; 8: 1155-1166.
39. Sotiriou C, Khanna C, Jazaeri AA et al. Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn 2002; 4: 30-36.
40. Farmer P, Iggo R, Becette V et al High quality gene expression microarray data from a multicentre prospective trial: results of the first microarray analysis in the EORTC 10994/BIG 00-01 study. 4th European Breast Cancer Conference. Eur J Cancer 2 2004; S99 (Abstr 155).
41. Ma XJ, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 607-616.
42. Eden P, Ritz C, Rose C et al. 'Good old' clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 2004; 40: 1837-1841.
43. Egyhazi S, Bjohle J, Skoog L et al. Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies. Clin Chem 2004; 50: 975-976.
44. Shi L, Tong W, Goodsaid F et al. QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies. Expert Rev Mol Diagn 2004; 4: 761-777.
45. Ein-Dor L, Kela I, Getz G et al. Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 2005; 21: 171-178.
46. Jarvinen AK, Hautaniemi S, Edgren H et al. Are data from different gene expression microarray platforms comparable? Genomics 2004; 83: 1164-1168.
47. Yauk CL, Berndt ML, Williams A, Douglas GR. Comprehensive comparison of six microarray technologies. Nucleic Acids Res 2004; 32: e124.
48. Tan PK, Downey TJ, Spitznagel EL Jr et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 2003; 31: 5676-5684.
49. Piper MD, Daran-Lapujade P, Bro C et al. Reproducibility of oligonucleotide microarray transcriptome analyses. An interlaboratory comparison using chemostat cultures of Saccharomyces cerevisiae. J Biol Chem 2002; 277: 37001-37008.
50. Unger MA, Rishi M, Clemmer VB et al. Characterization of adjacent breast tumors using oligonucleotide microarrays. Breast Cancer Res 2001; 3: 336-341.
51. Bakay M, Chen YW, Borup R et al. Sources of variability and effect of experimental approach on expression profiling data interpretation. BMC Bioinformatics 2002; 3: 4.
52. Kothapalli R, Yoder SJ, Mane S, Loughran TP Jr. Microarray results: how accurate are they? BMC Bioinformatics 2002; 3: 22.
53. Li J, Pankratz M, Johnson JA. Differential gene expression patterns revealed by oligonucleotide versus long cDNA arrays. Toxicol Sci 2002; 69: 383-390.
54. Kuo WP, Jenssen TK, Butte AJ et al. Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 2002; 18: 405-412.
55. Lee JK, Bussey KJ, Gwadry FG et al. Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol 2003; 4: R82.
56. Mecham BH, Klus GT, Strovel J et al. Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. Nucleic Acids Res 2004; 32: e74.
57. Barczak A, Rodriguez MW, Hanspers K et al. Spotted long oligonucleotide arrays for human gene expression analysis. Genome Res 2003; 13: 1775-1785.
58. Chiorino G, Acquadro F, Mello Grand M et al. Interpretation of expression-profiling results obtained from different platforms and tissue sources: examples using prostate cancer data. Eur J Cancer 2004; 40: 2592-2603.